source
- Novartis RNA drug acquired in $12B Avidity deal notches a trial winThe data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.BioPharma Dive · 1mo ago↗ source
- STAT+: Novartis doubles down on molecular glue strategySeniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The ReadoutSTAT · 1mo ago↗ source
- Biopharma pay report: Top-paid CSOs, CMOs of 2025Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News lo…Endpoints · 1mo ago↗ source